Pioglitazone Nanoparticles Development, Characterization, Optimization, and a Zebrafish Model Evaluation of its Teratogenic Safety

Abstract

Background: New nanoparticles (NPs) and biomaterials are utilized more frequently in biological research for vaccinations, diagnostic procedures, and drug administration. Nanomaterials are materials with d50 value from 1 to 100nm. They are also found in various consumer goods, the environment, and work. Thus, it has become crucial for the appropriate development of nanotechnology to assess the safety and potential therapeutic applications of these nanomaterials. The BCS Cass II medication pioglitazone hydrochloride, used to treat hypoglycaemia, has poor bioavailability after oral treatment because it dissolves poorly in gastrointestinal fluids. background: New nanoparticles and biomaterials are utilized more frequently in biological research for vaccinations, diagnostic procedures, and drug administration. They are also found in various consumer goods, the environment, and work. Thus, it has become crucial for the appropriate development of nanotechnology to assess the safety and potential therapeutic applications of these nanomaterials. The BCS Cass II medication pioglitazone hydrochloride, used to treat hypoglycaemia, has poor bioavailability after oral treatment because it dissolves poorly in gastrointestinal fluids. Objective: This study aimed to create adjusted pioglitazone nanoparticles to decrease dose-related side effects and prolong its release when used against type 2 diabetes. objective: This study aimed to create adjusted pioglitazone nanoparticles to decrease dose-related side effects and prolong its release when used against type 2 diabetes Methods: The emulsion solvent evaporation approach was used to create nanoparticles utilising HPMC K15M and Eudragit S100 as polymers, and Tween 80 as a surfactant. On framed nanoparticles, in-vitro evaluation approaches for drug-polymer compatibility, percentage yield, particle size, zeta potential, polydispersity index, surface morphology, encapsulation effectiveness, and in-vitro drug release study were used, followed by in-vivo acute toxicity experiment. Conclusion: From the obtained data, it can be said that a suitable optimized formulation of pioglitazone nanoparticles was prepared, which offered extended drug release of 95% in 10 hours.